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Version Amendments 4
1. Reformatted as a network guideline 2. Inclusion of flowsheet for recording relapses 3. Removed dosing of low-molecular heparin and referred to separate guideline 4. Included reference to PREDNOS2 study for patients with frequently relapsing disease 5. Removal of Prograf as recommended tacrolimus preparation in line with NUH policy to move to prescribing generic preparations 6. Inclusion of checking of hepatitis B status prior to giving first rituximab dose 7. Amendment to genetic investigations for children with steroid resistant nephrotic syndrome to amalgamate different tests as single sample for NGS of all known SRNS mutations 5
1. Insertion of relevant hyperlinks to the EMEESY website, InfoKID and other sources of public information 2. Removal of information on PREDNOS study (now completed but awaiting results) 3. Re-insertion of information on metolazone as now available again. 
Objectives of the guideline
With regard to initial presentation: 1. Describe presentation of typical and atypical nephrotic syndrome.
2.
Know what investigations to carry out for a child presenting with nephrotic syndrome.
3.
Recognise how to diagnose and manage hypovolaemia in the nephrotic state. 4 .
Know when and how to give intravenous albumin safely.
5.
Know when to discuss with a paediatric nephrologist and when to refer. 6.
Know how long children need to remain in hospital during the initial episode and what the purpose of the hospital admission is. 7.
Be familiar with the information about nephrotic syndrome that parents need at discharge. 8 .
Know how to follow-up children with nephrotic syndrome in the out-patient clinic and what to do at each consultation.
With regard to relapsing disease: 1.
How to define and manage a relapse.
2.
What the role of the linked renal nurse is during the initial episode and following discharge.
3.
Understand what other members of the multi-disciplinary team should be involved in the care of a child with nephrotic syndrome. 4 .
Know how to recognise and manage frequently relapsing nephrotic syndrome.
5.
Know how to prevent and manage infective complications of nephrotic syndrome. 6 .
Know when to refer to a shared care clinic 7.
Have knowledge of current evidence base for nephrotic syndrome care and knowledge of studies currently in progress. Version 5: July 2017
Background
Nephrotic syndrome is characterised by heavy proteinuria (protein:creatinine ratio > 250 mg/mmol which corresponds to the ISKDC definition of nephrotic-range proteinuria of 40 mg/m2/h) 1 , hypoalbuminaemia (serum albumin <25 g/l) and oedema: . It is an uncommon childhood condition with an annual incidence in the UK of only 2 per 100,000 children. It is more common in children from South Asia with an incidence up to 16 per 100 000 children 2 .
There are many different causes of nephrotic syndrome, but the majority of cases (over 90%) are primary and due to minimal change disease (MCD) 3 . Approximately 80% of children presenting with nephrotic syndrome will respond to prednisolone and this is the most important factor in terms of management and prognosis.
Nephrotic syndrome is thought of as a relatively benign condition; however the mortality rate remains around 0.5-1%. There is significant acute and long term morbidity and almost half children presenting with an initial episode will develop frequently relapsing disease, therefore it is appropriate to consider early referral of all patients to the paediatric renal team.
Assessment and Management of Initial Episode

Clinical history
To include history of:
 Atopy  Immunisations  Natural childhood infections (particularly Varicella Zoster)  Family history (particularly renal disease and thrombophilia)
All children should be admitted. 
Clinical examination
Baseline investigations
Children presenting with typical nephrotic syndrome are frequently over-investigated. Providing the history is consistent with typical nephrotic syndrome (see section 2.4 below), the following investigations are all that is required as a baseline assessment for diagnosis and surveillance for complications
Urine tests Blood tests Urinalysis for protein and blood
Electrolytes, urea and creatinine, Protein:creatinine ratio (early morning sample if possible Bone profile (including albumin) Full blood count Varicella zoster immunity status Raised urea or haemoglobin may be markers of hypovolaemia. Elevated creatinine can indicate atypical nephrotic syndrome and is an indication for discussion with a paediatric nephrologist.
Plasma lipids, complement and hepatitis serology are not relevant investigations for a first episode of typical nephrotic syndrome.
Plan tests: single venepuncture is ideal in children who may be difficult to bleed because of oedema. Femoral stabs should never be performed as thrombosis is a described complication.
On-going blood tests are only necessary for children receiving albumin infusions, diuretics or to follow-up initial abnormal results.
Typical versus atypical nephrotic syndrome
Children with an atypical initial presentation of nephrotic syndrome are less likely to have minimal change disease and may not be responsive to steroids. They may require biopsy before initiating treatment and should always be discussed with a paediatric nephrologist.
Criteria
Typical nephrotic syndrome 
Indications for discussion with a paediatric nephrologist at presentation
The nephrotic state can be complicated by hypovolaemia, thrombosis and infection. If there are any of the following features during the initial presentation, the child should be discussed with a consultant paediatric nephrologist:  Any atypical features as above  Suspicion of hypovolaemia from clinical assessment or elevated haemoglobin/urea  Before giving intravenous albumin
Management
Nephrotic syndrome treatment aims to induce remission with steroids (most patients respond within 7-14 days), and therefore promote diuresis. All other therapies are symptomatic and aimed at preventing complications. Children who do not respond to prednisolone within 28 days will require referral to paediatric nephrology for a renal biopsy. All doses should be rounded to the nearest 5 mg. A "steroid warning card" should be provided for the patient to carry.
Gastroprotection
Despite large doses of steroids, few children experience gastritis symptoms. If necessary, children may be given ranitidine or omeprazole (10 mg/5 ml liquid if <15 kg) as gastroprotection whilst on high dose steroids.
Assessment of hypovolaemia
Hypovolaemia in the nephrotic state is a common but serious complication which increases the risk of thrombosis. Clinical indicators of hypovolaemia include tachycardia, hypertension, cool peripheries and delayed capillary refill time. Laboratory parameters suggesting hypovolaemia include elevated urea or haemoglobin.
Diuretics without albumin must not be given in hypovolaemia due to the risk of thrombosis.
If hypovolaemia is severe (such as with noticeably cool peripheries, abdominal pain or elevated urea) then consideration should be given to treatment with intravenous albumin (section 2.6.4.2) and to thromboprophylaxis (section 2.6.5). Normal saline or other isotonic crystalloid may be given if albumin is not immediately available.
Oedema and ascites
A gentle fluid restriction is also usually beneficial to minimise oedema. Suggested fluid intake: <5 yrs = 750 ml >5 yrs = 1 litre A "no added salt" diet is recommended (see section 2.7) Version 5: July 2017
Diuretics
These must only be used if severe and worsening oedema/ascites in the absence of hypovolaemia. Furosemide alone may be tried initially but if oedema is severe, the synergistic action of furosemide with spironolactone may be required. Doses are:
 Furosemide 0.5-1 mg/kg twice daily  Spirinolactone 1 mg/kg twice daily If oedema persists, a thiazide, metolazone, may be added under the guidance of a consultant paediatric nephrologist. The dose is: 1 m -12 y: 100-200 microgram/kg once daily initially, increased if necessary to twice daily for resistant oedema. 12 -17 y:
5-10 mg once daily initially, increased if necessary to twice daily for resistant oedema.
Albumin infusions
Albumin infusion is only indicated in symptomatic hypovolaemia or severe diuretic resistant oedema. It should be administered with great caution with frequent monitoring of vital signs until at least two hours after the infusion is completed. Dose:  Shock = 4.5% albumin 20 ml/kg over 30-60 mins repeated if necessary. If volume status remains depleted, discuss with regional paediatric intensive care before giving further boluses.  Mild hypovolaemia + oedema = 20% albumin 5 ml/kg (1g/kg) over 4 hrs with IV furosemide 1 mg/kg halfway and/or at the end of the infusion provided signs of hypovolaemia have resolved (mid and end-point clinical evaluation should be carried out)  Severe diuretic resistant oedema = 20% albumin 5 ml/kg (1g/kg) over 4 hrs with IV furosemide 1mg/kg half way through infusion Ensure that your individual hospitals' transfusion policy will allow for infusion of 20% albumin over >3 hours.
Unless there is experience in giving 20% albumin and facilities for high-dependency monitoring, condition should be given to discussion with a paediatric nephrologist with a view to transfer to Nottingham or a more local critical care bed. 
Risk of thrombosis
Dietary advice
A dietitian should see the child and family. A balanced no added salt diet is recommended.
The dietetic advice to achieve this is to avoid the addition of salt in cooking and at the table.
To reduce the intake of processed foods parents should select foods which contain <0.5 g Na per 100 g weight of food. This information is usually available on the packaging. Compliance with a no added salt diet will aid adherence to the fluid restriction and encourage good blood pressure control. The diet should be nutritionally balanced with an emphasis on healthy eating and the avoidance of a high saturated fat intake.
If a dietitian is unavailable, advice about low salt foods is available on the EMEESY website (professional area/dietietic information).
Parental education
Nephrotic syndrome is a significant diagnosis. The family needs to be aware that the risk of relapse is >80% and they should know how to detect and treat it. Making adequate information available for the family is essential. All carers should receive the Childhood Nephrotic Syndrome booklet or be signposted to the infoKID website (www.infokid.org.uk) and be given a Nephrotic Diary or equivalent notebook to record daily urine results. They should be shown how to test urine and record in the diary before discharge.
Referral to the paediatric nephrology liaison nurse or link paediatric nephrology nurse (if available) should be routine.
Patient support information is available on the internet through. NeST (www.nstrust.co.uk) and Nephcure (www.nephcure.org). Opportunity should be given to discuss any issues with parents that arise from seeking information from the internet.
Discharge planning
Children will normally spend several days in hospital following a first presentation with nephrotic syndrome. Even if there is not significant oedema, a short admission will be necessary to teach children and their parents about nephrotic syndrome. For many children with their initial presentation, there is significant oedema and discharge date will be determined according to when the child is judged to be cardiovascularly stable. Version 5: July 2017
Each day during their in-patient stay, children should have a thorough assessment of their fluid status including accurately completed fluid balance charts, regularly blood pressure monitoring and a daily weight. They should be examined daily for extent of oedema and signs of hypovolaemia.
Discharge checklist
Before discharge, parents/carers should know:  how to dipstick the child's early morning urine and record this in a daily diary.  how to recognise a relapse  whom to contact for advice  appropriate fluid and dietary advice  steroid and immunosuppression advice 3. Out-patient management
Out-patient follow-up until remission
Most children will be discharged from their initial episode of nephrotic syndrome before they enter remission. All will be taking high-dose steroids and some will also be taking regular diuretics. These children should be reviewed in an out-patient clinic (review in a rapid access clinic or as a ward attender is also suitable) at least every week. Parents should be encouraged to bring urinalysis diaries to all out-patient appointments.
The consultation should include a review of medication and any side-effects experienced. Weight, blood pressure and urinalysis should be done before seeing the doctor. Examination should include an assessment of volume status as above.
Routine out-patient follow-up for the first 6 months
Children should be seen approximately monthly for the first 6 months. The purpose of the regular review is:  Assess for side-effects of steroids (weight gain, Cushingoid appearance, striae, hypertension, behavioural side-effects, growth)  Review urinalysis diary and reinforce the importance of daily urine testing and recording  Confirm steroid dosing  Provide further education opportunities, especially the management of relapses
Management of relapses
Relapse within the first year is common (86%) but can also occur years after the initial presentation. Relapse can follow viral infection or occasionally immunisation.
A relapse is defined as proteinuria of +++ or more for 3 consecutive days.
Standard treatment for a relapse is prednisolone 60 mg/m 2 /day (maximum dose 80 mg) given once daily until remission, which is defined as urinary protein negative or trace for 3 consecutive days. This is followed by prednisolone 40 mg/m 2 /alternate day (maximum dose 55 mg) for 28 days. Thereafter steroids are usually stopped but may taper slowly if this is not the first relapse or the relapse has occurred on steroid therapy.
It is suggested that children are assessed face to face for their first relapse to:
 Ensure that the relapse has been diagnosed correctly  Check for hypovolaemia  Confirm daily prednisolone dose and duration Version 5: July 2017
 Give parameters to parents that should prompt further hospital review such as worsening oedema or the development of abdominal pain.  Plan for further routine out-patient review within the next month.
For further relapses, it is not always necessary for a child to be seen but parents are encouraged to phone their local contact (e.g. paediatric nephrology liaison nurse, paediatric renal link nurse (if available), local SPIN paediatrician, paediatric ward out of hours) before initiating high dose prednisolone. Prednisolone treatment is frequently delayed for at least 5 days unless the child is becoming oedematous since a small number of children will remit spontaneously. Any children with abdominal pain or who are otherwise unwell should be reviewed by a doctor.
Routine immunisations in nephrotic syndrome
Routine vaccinations should be given as outlined in the DoH handbook. Live vaccines should not be given to children who are on or have recently been taking immunosuppressive medication as defined below:
Immunosuppression in the context of immunisation is defined as any child who is receiving or has received in the last 3 months: (a) Prednisolone 2 mg/kg/day for > 1 week (b)
Prednisolone 1 mg/kg/day or equivalent for 1 month (i.e. 40 mg/m 2 alternate days) (c)
Lower doses of prednisolone combined with cytotoxic drugs (d)
Long term lower dose immunosuppression.
Children with frequently relapsing or steroid resistant nephrotic syndrome should be considered for the annual influenza vaccine and additional non-live vaccines such as swine flu.
In some instances where the risk of relapse is high, immunisation may be deferred. This requires discussion with the consultant.
Chicken pox contact
Chicken pox whilst immunosuppressed can be a very serious illness. Varicella zoster immunity status should be known (and documented) in each nephrotic patient.
Children who are non-immune and have close contact (household or same school class etc.) with chicken pox may require post-exposure prophylaxis (VZIG or acyclovir, according to local policies).
All children with nephrotic syndrome who are varicella non-immune should be vaccinated against chicken pox at the first opportunity of their being non-immunosuppressed (as defined above). Consideration should also be given to immunising non-immune siblings. These issues should be raised with the parents and GP at the initial episode.
Data collection
Careful recording of clinical information is key to guiding future treatment. Any relapses since the previous clinic should be recorded with the following information:  Date of relapse  Prednisolone dose at the time of relapse (also note if steroid dose reduced within two weeks of relapse)  Treatment given  Time until remission This information may be easily referenced by keeping a flowsheet such as that in appendix 1. It is hoped that future patients might be registered within a multi-centre registry. Version 5: July 2017
Management of FRNS and SDNS
The above treatment supposes the nephrotic syndrome is steroid sensitive. However, at least 40% of children will have regular relapses and have difficulty coming off steroid medication. These two sub-types of nephrotic syndrome and their management are described below.
Is is anticipated that children with frequently relapsing nephrotic syndrome (FRNS) and steroid dependent nephrotic syndrome (SDNS) will be managed by SPIN paediatricians or paediatric nephrologists.
FRNS is defined as three relapses (including the initial episode) within the first year or two or more relapses in any 6 months thereafter. SDNS occurs when children have two consecutive relapses on prednisolone or within two weeks of discontinuing it. The two conditions frequently occur together. Both FRNS and SDNS require second line treatments.
The following second-line treatments are available. All children suitable for a second-line treatment should be discussed with a consultant paediatric nephrologist first.
All children with frequently relapsing disease should be considered for the PREDNOS2 study which is an evaluation of a 6-day daily course of low-dose prednisolone given at the time of an upper respiratory tract infection on its ability to prevent a nephrotic relapse. More details can be found on the shared area (Nottingham patients) or on the PREDNOS2 website or by discussing with the link paediatric nephrologist.
The algorithm for treating FRNS/SDNS is summarised in the figure.
Tapering and long-term low-dose steroids
Children who received a standard 2-month course of prednisolone for the initial episode may benefit from a slowly tapered course as described in section 2.6.1 above.
Prednisolone may be continued long-term at low dose (e.g. 5 mg) on alternate days and this is the simplest form of prophylactic therapy for FRNS.
Prophylactic steroids to cover intercurrent illness
It may be possible to prevent nephrotic relapses by giving a low dose of daily steroids for 5 days at the time of an upper respiratory tract infection without waiting for proteinuria to develop. This practice has the potential to make a large impact on the long-term steroid burden of the child and is the subject of a national multi-centre trial, PREDNOS2. All children with frequently relapsing nephrotic syndrome should be considered for entry into this trial, which is open until April 2018.
Levamisole
Levamisole may be more efficacious over steroids alone. The dose is 2.5 mg/kg (maximum 150 mg) on alternate days. It is available as 50 mg tablets which may be crushed. Sideeffects of levamisole are rare but include leucopenia, gastro-intestinal effects and vasculitis. A full blood count should be monitored whilst the child is taking levamisole. More importantly, parents should be counselled to seek medical attention and request a full blood count if their child has any unusual or severe infections.
Levamisole may be best suited to children who are very frequent relapsers but not steroiddependent. It is a well-tolerated drug and should be considered as the first-choice secondline agent in this sub-group of children with nephrotic syndrome.
Its efficacy may not become apparent for several months and it is best suited with a slow steroid taper when it is commenced. Generally it is used initially in combination with low-dose Version 5: July 2017 steroids but may subsequently be used as monotherapy 6 . It is usually continued for at least 1-2 years. There appears to be no sustained effect once levamisole is discontinued.
Cyclophosphamide
This has been shown to significantly reduce the risk of relapse in FRNS 7 . The dose is 3 mg/kg once daily for 8 weeks. Dose reductions are required in renal impairment and obesity, discuss with pharmacist. It is available in 50 mg tablets which may not be crushed since it is a cytotoxic drug. Doses close to 75 mg may be achieved by giving 50 mg and 100 mg on alternate days. Children who are unable to take tablets will need to have cyclophosphamide suspension made by the hospital pharmacy. The suspension has a 4-week expiry and liaison with the paediatric pharmacist prior to use is necessary to ensure a continuous supply. Further information for your local pharmacist is available on the pharmacy page of the EMEESY website.
Cyclophosphamide is usually tolerated well. It may be associated with leucopenia and a weekly full blood count is necessary during throughout the 8-week course. Before commencing cyclophosphamide, there must be arrangements made:
 Who does the weekly full blood count?  Who will chase the result?  Who will action any changes of cyclophosphamide dose?
Dose alterations should be made as follows:
Continue previous dose 1. 5 
-2
Reduce dose to 50% <1. 5 Stop and restart only when neutrophil count >2
If the neutrophil count remains stable for the first 4 weeks of the course, the full blood count may be checked fortnightly for the remaining 4 weeks of the course.
Cyclophosphamide may lead to hair thinning. Usually this is no more than increased hair loss on brushing but occasionally it may be more noticeable than this, particularly in older children, and rarely may result in total alopecia. Hair growth normalises after cessation of cyclophosphamide.
Cyclophosphamide may also cause bladder irritation. Mesna is not necessary with oral cyclophosphamide but children should be advised to have a good fluid intake whilst taking it.
The long-term risk of infertility for a single course of cyclophosphamide (168 mg/kg) is minimal 7 . There is a small increased risk of malignancy following cyclophosphamide. Latta 7 estimated this as 0.2% although the follow-up periods in the studies were relatively short.
It is important to counsel parents/carers of all these side-effects before commencing cyclophosphamide treatment and good practice to document this in the medical notes. An information sheet on the use of cyclophosphamide in nephrotic syndrome is available on the Medicines for Children website.
Cyclophosphamide is the preferred second-line agent in pre-pubertal children where there is steroid dependence. In peri-and post-pubertal children consideration may be given to starting tacrolimus ahead of cyclophosphamide due to a theoretical increased risk of gonadal toxicity at this age. Version 5: July 2017
Intravenous cyclophosphamide
Intravenous cyclophosphamide is a suitable alternative to oral cyclophosphamide where there is concern about concordance with medication for the treatment of FRNS/SDNS and is effective at a dose of 500 mg/m 2 monthly for 6 months 
Tacrolimus
Calcineurin inhibitors are effective at reducing frequency of relapses in FRNS 5 . Tacrolimus is preferred to ciclosporin due to the lack of cosmetic side-effects (gingival hyperplasia and hirsutism) 9 . Tacrolimus will usually be considered as a third-line agent but may be used as a second-line agent if there are particular concerns about side-effects of cyclophosphamide. Tacrolimus will usually be continued for 2 years in the first instance. Frequent tacrolimus trough levels (EDTA sample) are required when initiating tacrolimus. Before it is started in a local hospital, there must be provision for tacrolimus results to be available within 48 hours (ideally 24 hours). Tacrolimus levels are usually only measured in hospitals where the drug is used frequently (most commonly with a large transplant service). If samples are sent out to an external laboratory, discussion with the local biochemist will be required to ensure that samples are not batched before sending and that results can be accessed directly from the external lab.
Tacrolimus is available in various forms: Adoport, Modigraf (soluble granules) and Advagraf (once daily). Children should not use different brands interchangeably. If there is a need to switch from one brand to another, an early level should be performed. Current pharmacy advice is to prescribe by brand name to avoid these confusions.
Tacrolimus capsules are available in the following doses: 0.5 mg, 1 mg and 5 mg. Modigraf is a granular form available in sachets on 0.2 mg and 1 mg doses. It is given by diluting in water first and is the preferred form of tacrolimus for children unable to swallow capsules as tacrolimus capsules need to be opened and dissolved in water and tacrolimus suspension prepared as a "special" has poorer bioavailability and unreliable dosing due to its tendency to concentrate towards the bottom of the bottle.
The starting dose of tacrolimus is 0.15 mg/kg twice daily with a maximum starting dose of 5 mg bd. Doses should be adjusted to achieve an initial 12-hour trough of 5 -8 ng/ml. Once the child is established and well-controlled on tacrolimus, on-going trough level monitoring will be required at least 3-monthly. Renal function and full blood count should also be measured 3-monthly and liver function at least 6-monthly. Trough levels for children who are wellcontrolled on tacrolimus should be maintained at 4 -6 ng/ml. Dose related side-effects are common in the initial period. They include headache, tremor, abdominal pain and visual disturbance. These side effects usually indicate a reduction in dose is needed. Tacrolimus may have long-term effects on renal function. Regular monitoring of renal function is required. Tacrolimus may cause reduced insulin sensitivity. Urinalysis will be regularly checked in clinic. If there is any glycosuria, a fasting blood glucose should be measured.
If children remain relapse free after 2 years on tacrolimus, it should be stopped. If there is an early relapse, it should be recommenced following induction of remission with high-dose prednisolone. For children on tacrolimus longer than 2 years, a renal biopsy should be carried out to look for evidence of nephrotoxicity (excessive glomerulosclerosis with or without arteriolar hyalinosis). Where there is significant nephrotoxicity, it will usually be necessary for children to switch to non-nephrotoxic immunosuppression such as mycophenolate or rituximab.
Mycophenolate mofetil
This is an antiproliferative agent in the same class, but more effective than, azathioprine. It may be effective as an alternative or add-on agent for children who relapse on tacrolimus.
If used in combination with tacrolimus, the dose is 300 mg/m 2 bd but since it is associated with gastrointestinal upset (abdominal pain and diarrhoea) it is better tolerated if started at half-dose and increased gradually over 2 -3 weeks. The dose if used without tacrolimus is 600 mg/m 2 bd and again this should be started lower and gradually increased. Version 5: July 2017
Mycophenolate comes as either 250 mg capsules or 500 mg tablets and is available in a wide range of generic preparations that are bio-equivalent. It is also available as Cellcept suspension (1 g in 5 ml).
Rituximab
The anti-CD20 monoclonal antibody, rituximab has been shown to be effective in the treatment of nephrotic syndrome 10 .
Where it has been used in FRNS/SDNS, in most cases it consolidates a remission for at least 6 months, allowing other immunosuppressive agents to be reduced or even withdrawn.
NHS England has published a commissioning policy for the use of Rituximab in FRNS 11 . It may be accessed here. The following points are salient:
 It may only be given when tacrolimus and mycophenloate have been shown to be inffective.  Tacrolimus must be given for a minimum of 6 months; mycophenolate must be given for a minimum of 3 months  It must be given in a paediatric renal centre (Nottingham, Leicester or Sheffield)  Viral serology (hepatitis B &C, EBV, CMV, parvovirus, adenvovirus and varicella) must be checked before giving
The dose is a matter for discussion. NHSE recommend two intravenous infusions of 750 mg/m2 given 2 weeks apart but in Nottingham we have shown that a single dose of 375 mg/m 2 can produce B-cell depletion and a relapse-free period of at least 6 months.
Rituximab is given at gradually increasing rates and takes several hours to give. As there is a risk of serum sickness reactions, it is given with steroid and anti-histamine cover. A monograph for rituximab infusion is available on the EMEESY pharmacy information page.
Prior to rituximab infusion, in addition to the above viral serology, baseline CD19 and immunoglobulins should be measured. After rituximab is given, CD19 count and immunoglobulin levels should be sent regularly to document the duration of B-cell repopulation. As B-cell repopulation may occur with a new clone of B-cells, a single dose of rituximab may be curative, or at least disease-modifying.
Most children will relapse with B-cell population. Until better data are available, it is advisable to adopt a wait and see approach following B-cell repopulation. If there is a prompt relapse, further doses of rituximab may be given with a frequency that corresponds to the initial duration of B-cell depletion. It is not necessary to measure CD19 counts routinely following repeat doses but it is recommended that this is done prior to each subsequent dose.
For children who do not relapse upon B-cell repopulation, it may be appropriate to reconsider other prophylactic immunosuppressants, particularly mycophenolate mofetil as an alternative to further doses of rituximab.
Long-term effects of rituximab are not known. There have been case reports of progressive multifocal leucoencephalopathy although it is not clear whether these are a result of rituximab per se or simply heavy immunosuppression. There are also small numbers of case reports of potentially fatal lung injury with a clear association with rituximab. Repeated doses of rituximab have been shown to result in persistent hypogammaglobulinaemia. On the current evidence, it is advised that no more than 4 prophyactic doses of rituximab are given before waiting to see if the child has entered a long-term remission. Immunoglobulins should be checked after each Rituximab infusion and repeated regularly if low. Children with immunoglobulin levels below the normal range who require further prophylactic treatment for relapses should only be given further rituximab doses if other options are unsuitable.
